ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Hierarchical Channeled Graphitized Nanoarchitecture as a Diagnostic Platform for Maternal Fever Warning.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The precision and effectiveness of nano-diagnostic platforms rely on the deliberate design of advanced nanomaterials, aiming to address the clinical challenge, such as sensitive diagnosis of infectious chorioamnionitis-associated fever (CAM) versus non-infectious epidural-related maternal fever (ERMF), while also expanding the scope of nano-diagnostic technologies to include bio-detection like glycomics, which are cohesively linked to disease but require complex procedures. Here, we designed a hierarchically channeled graphitized nanoarchitecture (HPGC-Z67) as a novel nano-diagnostic platform. HPGC-Z67 features high graphitization and interconnected multi-scale channeled structures that facilitate N-glycan retention and mass transfer in expanded porous channels. Notably, compared to traditional protocol, this HPGC-Z67 platform reduces processing time by about 25 min and cost by approximately CNY 30 per plasma sample, making it suitable for large-scale clinical diagnostics. The HPGC-Z67 nano-diagnostic platform enables sensitive extraction of N-glycan profiles from 150 plasma samples. Notably, two pivotal N-glycans are identified, one sensitive to infectious fever (IF-sensitive) and the other to non-infectious fever (n-IF-sensitive), which together enable simultaneous differentiation of ERMF, CAM, and healthy controls with area under the curve values of 0.965 in the training set and 0.914 in the validation set, respectively. This HPGC-Z67 nano-diagnostic platform advances glycomics towards precise diagnostics and timely clinical intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.